References
  1. Osteoarthritis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Updated February 4, 2010. Accessed February 24, 2010.
  2. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351-358.
  3. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59:1207-1213.
  4. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):31S–38S.
  5. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905-1915.
  6. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000;60(3):555-574.
  7. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. Br Med J. 1995;311:22-26.
  8. Özgüney I. An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution. Expert Opin Pharmacother. 2008;9:1805-1816.
  9. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial. BMC Musculoskeletal Disord. 2005;6:1-9.
  10. Diclofenac Sodium [prescribing information]. Corona, CA: Watson Laboratories, Inc.
  11. Altman RD. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care. 2009;15:S236-S243.
  12. ACR draft treatment guidelines for knee, hip, and hand osteoarthritis [press release]. Philadeplphia, PA: Medscape Medical News; October 22, 2009.
  13. American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the Knee (Non-Arthroplasty): Full Guideline. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2008.
  14. Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative Effectiveness Review No. 4. Rockville, MD: Agency for Healthcare Research and Quality; September 2006. AHRQ Publication No. 06-EHC009-EF.
  15. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians; 2008.
  16. Hewitt PG, Poblete N, Wester RC, Maibach HI, Shainhouse JZ. In vitro cutaneous disposition of a topical diclofenac solution in human skin: effect of a multi-dose regimen. Pharm Res. 1998;15:988-992.
  17. Simon LS, Grierson LM, Naseer Z, Bookman AA M, Shainhouse JZ. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143:238-245.
  18. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164:2017-2023.
  19. Gurtovenko AA, Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B.2007;111:10453-10460.
  20. Notman R, Noro M, O'Malley B, Anwar J. Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes. J Am Chem Soc. 2006;128:13982-13983.
  21. Bookman AAM, Williams KSA, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171:333-338.
  22. Tugwell PS, Wells GA, Zev Shainhouse J. Equivalence study of a topical diclofenac solution (Pennsaid®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31:2002–2012.
  23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
  24. Arthritis. Meeting the challenge: at a glance 2010. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/chronicdisease/resources/publications/AAG/arthritis.htm. Updated January 28, 2010. Accessed December 30, 2010.
  25. Solaraze [package insert]. Melville, NY: Nycomed US, Inc; 2008.
  26. Shainhouse JZ, Grierson LM, Naseer Z. A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. March 2010. doi: 10.1097/MJT.0b013e3181d169b5.
Solaraze is a registered trademark of Nycomed US Inc.

INDICATION
PENNSAID® is a nonsteroidal anti-inflammatory drug (NSAID) used for treating the signs and symptoms of osteoarthritis of the knee(s).

IMPORTANT RISK INFORMATION

WARNING: CARDIOVASCULAR (CV) AND GASTROINTESTINAL (GI) RISK
    Cardiovascular Risk
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious blood clots in the heart, or cause a heart attack or stroke. These risks can cause death. The risk may increase the longer NSAIDs are used. Patients who have heart disease or are at risk for heart disease may be at greater risk
  • Do not use PENNSAID in patients who are in the hospital for heart bypass surgery grafts
    Gastrointestinal Risk
  • NSAIDs cause an increased risk of serious stomach problems or problems in the intestines. Patients could bleed or develop a hole in their stomach or intestines. All of these problems can cause death. These problems can happen at any time with no warning when using NSAIDs. Older patients are at greater risk for these problems

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG.
PENNSAID is a registered trademark of Nuvo Research Inc. Other brands are trademarks of their respective owners. © 2011 Covidien